相关临床试验
782
250 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1829
进行中（未招募）
180
23.0%
已完成
343
43.9%
Enrolling By Invitation
6
0.8%
尚未招募
64
8.2%
招募中
67
8.6%
暂停
5
0.6%
终止
10
1.3%
Unknown
98
12.5%
撤回
6
0.8%
暂无批准数据
- Researchers at King's College London identified KV7.4 as the main active KV7 channel in the uterus, offering a potential new drug target for delaying preterm labor. - Treating human and mouse myometrium with retigabine, a KV7 channel opener, reduced uterine contractions in laboratory studies. - In a mouse model of preterm birth, retigabine delayed preterm delivery, providing proof-of-principle for repurposing KV7 activators. - The findings, published in Communications Medicine, could open new treatment avenues for spontaneous preterm birth, which affects about 1 in 12 babies in the UK.
- King's College London & Guy's and St Thomas' PET Centre acquired two identical Biograph Vision Quadra total-body PET/CT scanners in late 2024 and early 2025, nicknamed the "twins." - The scanners' high sensitivity enables roughly half the radiation dose for patients and staff while scanning patients much faster, improving clinical efficiency. - The TOTEM study, with 1,400 patients recruited, is developing standardized total-body PET/CT protocols and has validated ultra-low-dose CT approaches within about six weeks. - An oncology trial using the [18F]FSPG tracer can predict head-and-neck cancer treatment outcomes within four weeks, versus 12 weeks for standard FDG scans.
- Researchers at King's College London found that urolithin A, a compound produced by gut bacteria from ellagitannins in pomegranates, walnuts, and berries, improved heart function in animal and human tissue models of heart failure with preserved ejection fraction (HFpEF). - In animal models of HFpEF, urolithin A improved heart function by as much as 80% compared to untreated models, reducing stiffness and improving the heart's ability to relax. - The compound acts through a previously unrecognized mechanism, directly modifying the Cys42 site of the PKGIα protein, which plays a central role in heart muscle relaxation. - The findings identify PKGIα as a new therapeutic target for HFpEF, though clinical trials in patients are still needed to confirm whether the benefits translate to humans.
- A first-of-its-kind study from King's College London linked coordinated changes in circulating B and T cells to survival outcomes in melanoma patients receiving immunotherapy. - Patients whose B and T cells showed renewed activation and expansion within the first six weeks of treatment had better outcomes, including improved survival. - Patients with immature or poorly functioning B cells, or weaker pre-treatment anti-cancer responses, had poorer survival, while certain T cell subtypes were linked to side effects. - The findings, based on 24 patients and 25 healthy volunteers using mass cytometry, point toward less invasive blood-based biomarkers to guide melanoma treatment decisions.
- The International Single Cell Mass Spectrometry (iSCMS) Conference and BMSS Single Cell MS Meeting will convene 6–9 October 2026 at King's College London, with abstract submission extended to 15 August 2026. - The meeting will showcase single-cell mass spectrometry advances across cancer, immunology, microbiology, neuroscience, metabolism, and precision medicine, featuring 11 internationally recognised invited speakers. - The Single Cell and Spatial Omics Symposium 2027 will take place on 11 March 2027 at Biomedicum Helsinki, jointly organized with the Doctoral Programme in Biomedicine as part of the annual NASSA meeting. - Both events highlight how single-cell and spatial omics are transforming understanding of cellular heterogeneity in health and disease, providing unprecedented insight into treatment response and disease outcomes.
- A new Science study using NanoSeq sequencing found platinum chemotherapy left an average of 2,200 mutations per liver sample in children treated for hepatoblastoma, a burden typical of adult livers. - Mutation load rose with platinum exposure, with children receiving both cisplatin and carboplatin showing more mutations than those given cisplatin alone. - Liver cells carried far more mutations than blood cells despite systemic treatment, suggesting the liver processes or repairs platinum damage differently. - A separate Nature study of 544 patients identified chemotherapy-specific genomic signatures that appeared as early as 91 days after treatment began.
- A multi-ancestry genome-wide association study across 11 cohorts identified 26 independent genome-wide significant risk loci for fibromyalgia, establishing a clear biological basis for the condition. - The top association was found in the Huntingtin (HTT) gene, with a coding variant (rs149109767-A) conferring approximately 9% increased odds of fibromyalgia, revealing an unexpected link to Huntington's disease biology. - Heritability enrichment analyses showed exclusive enrichment in neural tissues and cell types, with the strongest signal in dentate gyrus neurons, confirming fibromyalgia as a nervous system disorder. - Polygenic risk scores stratified individuals by risk, with those in the highest quintile having 1.5-fold increased odds compared to the middle quintile, though diagnostic utility remains modest (AUC = 0.59).
- A King's College London study published in Nature Microbiology identifies the IL-1 immune pathway as critical in preventing Candida albicans from spreading and causing fatal disease. - Mice genetically modified to lack IL-1 developed severe, fatal infection when exposed to Candida albicans, confirming IL-1's protective role. - Fungal infections kill more than 2.5 million people annually, with Candida albicans alone responsible for almost one million deaths each year. - The findings could lead to a test identifying at-risk immunocompromised patients and to IL-1-targeting therapies as personalized prevention.
- A new European consensus statement published in The Lancet Diabetes & Endocrinology emphasizes that long-term success of incretin-based obesity therapies depends on comprehensive nutritional, functional, and psychological support. - The consensus recommends medical nutrition therapy delivered by qualified dietitians, regular body composition monitoring, and resistance training to mitigate lean mass loss of 24–30% during treatment. - Authors call for pre-treatment mental health screening, ongoing psychological support, and expanded access to multidisciplinary care to address current gaps and reduce health inequalities. - A systematic review of 417 IBT trials revealed fewer than 20% reported dietary or nutritional outcomes, highlighting significant research gaps in long-term safety and efficacy.
- Researchers from ICR, King's College London, and King's College Hospital developed DOSET, a novel statistical framework for early-phase CAR-T therapy trials that simultaneously evaluates safety and efficacy. - DOSET demonstrated superior performance in correctly identifying safe and effective doses compared to existing methods, particularly in small-sample settings common in CAR-T studies. - The design allows trials to stop early when treatments appear ineffective or unsafe, reducing patient exposure to suboptimal doses. - Published in ESMO Open, DOSET marks the first publication of a novel statistical trial design from ICR-CTSU's Early Phase and Adaptive Trials Group for a real clinical trial.
